For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue from collaborative arrangement | 0 | 0 | 65,343 | - |
| Research and development | 13,333,329 | 14,521,407 | 16,090,902 | 18,733,584 |
| General and administrative | 7,877,126 | 8,563,112 | 9,024,970 | 8,613,895 |
| Total operating expenses | 21,210,455 | 23,084,519 | 25,115,872 | 27,347,479 |
| Loss from operations | -21,210,455 | -23,084,519 | -25,050,529 | -27,347,479 |
| Interest income | 552,108 | 610,638 | 808,077 | 1,106,758 |
| Interest expense | 0 | 0 | - | - |
| Change in fair value of common stock warrant liabilities | 22,515,730 | 1,878,010 | -3,712,872 | - |
| (loss) gain on investment in affiliated entity | -589,618 | 776,373 | 695,131 | 324,251 |
| Net unrealized gain on available-for-sale equity securities | 205,259 | 759,289 | 140,234 | 1,330,811 |
| Other expense, net | -1,938,236 | -703,183 | -482 | -579,819 |
| Net loss | -45,496,672 | -23,519,412 | -19,694,697 | -25,165,478 |
| Basic (in dollars per share) | -0.87 | -0.61 | -0.51 | -0.89 |
| Basic (in shares) | 52,168,694 | 38,830,053 | 38,613,653 | 28,140,497 |
| Diluted (in dollars per share) | -0.87 | -0.61 | -0.51 | -0.89 |
| Diluted (in shares) | 52,168,694 | 38,830,053 | 38,613,653 | 28,140,497 |
INOVIO PHARMACEUTICALS, INC. (INO)
INOVIO PHARMACEUTICALS, INC. (INO)